| Literature DB >> 33372411 |
Guang Yang1, Ying Yuan1, Hongfeng Yuan1, Jiapei Wang1, Haolin Yun1, Yu Geng1, Man Zhao1, Linhan Li2, Yejing Weng2, Zixian Liu1, Jinyan Feng1, Yanan Bu1, Lei Liu1, Bingnan Wang2, Xiaodong Zhang1.
Abstract
Lysine succinylation (Ksucc) is an evolutionarily conserved and widespread post-translational modification. Histone acetyltransferase 1 (HAT1) is a type B histone acetyltransferase, regulating the acetylation of both histone and non-histone proteins. However, the role of HAT1 in succinylation modulation remains unclear. Here, we employ a quantitative proteomics approach to study succinylation in HepG2 cancer cells and find that HAT1 modulates lysine succinylation on various proteins including histones and non-histones. HAT1 succinylates histone H3 on K122, contributing to epigenetic regulation and gene expression in cancer cells. Moreover, HAT1 catalyzes the succinylation of PGAM1 on K99, resulting in its increased enzymatic activity and the stimulation of glycolytic flux in cancer cells. Clinically, HAT1 is significantly elevated in liver cancer, pancreatic cancer, and cholangiocarcinoma tissues. Functionally, HAT1 succinyltransferase activity and the succinylation of PGAM1 by HAT1 play critical roles in promoting tumor progression in vitro and in vivo. Thus, we conclude that HAT1 is a succinyltransferase for histones and non-histones in tumorigenesis.Entities:
Keywords: HAT1; epigenetic regulation; glycolysis; succinylation; tumorigenesis
Mesh:
Substances:
Year: 2020 PMID: 33372411 PMCID: PMC7857430 DOI: 10.15252/embr.202050967
Source DB: PubMed Journal: EMBO Rep ISSN: 1469-221X Impact factor: 8.807